



## Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

### Summary of Main Points from the Meeting held on Monday 21<sup>st</sup> November (Draft)

#### 2. Minutes and Summary Notes from last meeting

On account of the Trust response to the Covid-19 Pandemic, this meeting was held via Teams. The minutes and summary notes of the Medicines Group Meeting held on 18<sup>th</sup> July 2022 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

#### 3. Matters Arising

The Group noted the matters arising from the previous meeting.

#### 4. Business to be transacted by the Medicines Group

##### a) Formulary Applications

##### *Full Applications*

- **Declaration of conflicts of interest by Group members**

Declaration of any conflicts of interest by any Group members - Nil

- **Formulary applications**

##### *Full Applications*

- **Zerocream**

Requested by: Dermatology Department

Indication: Symptomatic treatment of flaking, dry or chapped skin, ichthyosis, traumatic dermatitis, sunburn, the dry stage of eczema and certain dry cases of psoriasis.

Proposal: Add to the formulary to replace 1<sup>st</sup> line use of E45

Cost: Cost saving of £5k annually based on usage of E45

Approval status: Approved by Chair's action on 24/08/2022 - For noting

**Outcome: Approved for addition to the Trust Formulary**

**Approved for Pharmacy automatic substitution**

- **Covid-19 Bivalent Vaccine (Spikevax®)**

Requested by: Microbiology

Indication: Vaccination against Covid-19 (as a Booster) of staff across both hospital sites WMUH Public Vaccination Hub in line with UKHSA Guidance.

Proposal: Add to the formulary as a new medicine

Cost: implication: Nil

Approval status: Approved by Chair's action on 24/08/2022 - For noting

**Outcome: Approved for addition to the Trust Formulary**

- **Covid-19 Bivalent Vaccine (Comirnaty®)**

Requested by: Microbiology

Indication: Vaccination against Covid-19 (as a Booster) of staff across both hospital sites and patients at WMUH Public vaccination Hub in line with UKHSA Guidance

Proposal: Add to the formulary as a new medicine

Cost implication: Nil

Approval status: Approved by Chair's action on 16/10/2022

For noting

**Outcome: Approved for addition to the Trust Formulary**

- **Monkeypox Vaccine (Jynneos®)**

Requested by: Microbiology



Indication: Vaccination against Monkeypox of staff and patients across both sites including off-site clinics and WMUH Public Vaccination Hub in line with UKHSA Guidance.

Proposal: Add to the formulary as a new medicine

Cost: implication: Nil

Approval status: Approved by Chair's action on 16/08/2022 - For noting

**Outcome: Approved for addition to the Trust Formulary**

- **Tecovirimat 200mg Capsules**

Requested by: Microbiology

Indication: Treatment of severe Monkeypox Infection in line with UKHSA Guidance

Proposal: Add to the formulary as a new medicine

Cost implication: Nil

Approval status: Approved by Chair's action on 14/11/2022 - For noting

**Outcome: Approved for addition to the Trust Formulary**

***Ex-panel***

- Nil

***Removals***

- Nil

***NICE Approved drug applications***

- **Cenobamate 50mg/100mg/150mg and 200mg Tablets (Ontozry®) in line with TA753**

**Outcome: Approved for addition to the formulary in line with NICE TA753**

- **Tucatinib 50mg and 150mg Tablets (Tukysa®) in line with NICE TA786**

**Outcome: Approved for addition to the formulary in line with NICE TA786**

- **Faricimab Intravitreal Injection in line with TA799 and TA800**

**Approved by Chair's Action on 16/08/2022 - For noting**

**Outcome: Approved for addition to the formulary in line NICE TA799 and TA800**

- **Icosapent Ethyl 998mg Capsules (Vazkepa®) in line with TA805**

**Proposal: Add to the formulary in line with NICE TA805**

**Outcome: Approved for addition to the formulary in NICE TA805**

- **Tralokinumab 150mg pre-filled syringes (Adtralza®) in line with NICE TA814**

**Outcome: Approved for addition to the formulary in NICE TA814**

- **Abrocitinib 100mg and 200mg Tablets in line with NICE TA814**

**Outcome: Approved for addition to the formulary in NICE TA814**

- **Alpelisib 50mg, 150mg and 200mg Tablets (Piqray®) in line with NICE TA816**

**Outcome: Approved for addition to the formulary in NICE TA816**

- **Sacituzumab Govitecan 180mg Infusion (Trodelvy®) in line with TA819**

**Outcome: Approved for addition to the formulary in NICE TA819**

- **Brolucizumab 120mg/ml Injection (Beovu®) in line with NICE TA820**

**Outcome: Approved for addition to the formulary in NICE TA820**

- **Azacitadine 200mg and 300mg tablets (Onureg®) in line with NICE TA827**

**Outcome: Approved for addition to the formulary in with NICE TA827**



- **Ryeqo® (Relugolix 40mg/Estradiol 1mg/Norethisterone 0.5mg) Tablets in line with TA832**  
**Outcome: Approved for addition to the formulary in line with NICE TA832**

#### ***Pharmacoeconomic Board requests***

- **Acalabrutinib for Lymphadenopathy (IFR Request)**  
Approved by the Pharmaceconomic Board on 29/07/2022 - For noting  
**Outcome: Noted**
- **Ritubimab for Myasthenia Gravis**  
Approved by the Pharmaceconomic Board on 12/10/2022 - For noting  
**Outcome: Noted**
- **Fosfamatinib for ITP**  
Approved by the Pharmaceconomic Board on 21/10/2022 - For noting  
**Outcome: Noted**
- **Obinutuzumab for Castleman's Disease**  
Approved by the Pharmaceconomic Board on 25/10/2022 - For noting  
**Outcome: Noted**
- **Tofacitinib for Ulcerative Colitis**  
Approved by the Pharmaceconomic Board on 07/11/2022 - For noting  
**Outcome: Noted**

#### ***FOC Schemes***

- **Risankizumab for Crohn's Disease on EAMS**  
FOC Scheme (EAMS) involving the use of Risankizumab in the management of Crohn's Disease  
Approved via Chair's action on 16/09/2022 - For noting  
**Outcome: Scheme approved for use within the Trust**

#### **4.2 Trust Medicines Policy**

- **TMP Section 20 - Admission and Discharge**  
Routine review and update
  - Updated in line with Cerner EPR
  - Removal of section relating to Lithium**Outcome: Approved**

- **TMP Section 30 - Supply of over-labelled and pre-packed medicines**  
Addition of the following as a clinical areas at WMUH that can operate in line with this policy:
  - Ambulatory Care
  - Syon 1
  - Chest Clinic 2
  - X-Ray
  - Haematology Day Unit
  - Occupational Health Department**Outcome: Approved**

#### **4.3 Medicines Optimisation**

Nil

#### **4.4 NICE Technical Appraisals and Guidance**



a) **NICE Technology Appraisals published July to October 2022**

**33 TA appraisals published from July to end October 2022**

**TA803 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (13/07/2022)**

**Formulary status / Action**

**Included on the formulary**

**Numbers likely to treat:**

**CWH: 3-5 patients per year**

**WMUH: 3-5 patients per year**

**TA804 Teduglutide for treating Short Bowel Syndrome (30/06/2022)**

**Formulary status / Action**

**Included on the formulary**

**Commissioned as a Specialist Paediatric Centre**

**Numbers likely to treat:**

**CWH: To be confirmed**

**WMUH: N/A**

**TA805 Icosapent Ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (13/07/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Action: Add to the formulary following receipt of application form from the Gastroenterology Team.**

**Application form included under section 4.1**

**TA806 Belimumab for treating lupus nephritis (Terminated appraisal) (13/07/2022)**

**Nil - Terminated Appraisal**

**TA807 Roxadustat for treating symptomatic anaemia in chronic kidney disease (13/07/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Not commissioned site as not a Specialist Renal Centre**

**TA808 Fenfluramine for treating seizures associated with Dravet Syndrome (08/07/2022)**

**Formulary status / Action**

**Not included on the formulary**

**CWFT is not a commissioned site for this NICE TA**

**TA809 Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (20/07/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Not commissioned site as not a Specialist Renal Centre**

**TA810 Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (20/07/2022)**

**Formulary status / Action**

**Included on the formulary**

**Numbers likely to treat:**

**CWH: 0**

**WMUH: 10-15 patients per year**

**TA811 Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (Terminated appraisal) (27/07/2022)**

**Nil - Terminated Appraisal**

**TA812 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (03/08/2022)**



**Formulary status / Action**  
Not included on the formulary  
Nil action as not recommended

**TA813 Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (03/08/2022)**

**Formulary status / Action**  
Not included on the formulary  
Not relevant to CWFT as if the patient has failed 2 or more TKIs then they would be referred to ICHT for treatment  
Numbers likely to treat:  
CWH: 0  
WMUH: 0

**TA814 Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (03/08/2022)**

**Formulary status / Action**  
Upadacitinib is included on the formulary  
Abrocitinib and Tralokinumab are not included on the formulary  
Action: Add Abrocitinib and Tralokinumab to the formulary following receipt of application forms from the Dermatology Team  
Update: Application form for Tralokinumab is included in Section 4.1  
Numbers likely to treat for Upadacitinib:  
CWH: 3-8 patients per year  
WMUH: 3-8 patients per year

**TA815 Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (10/08/2022)**

**Formulary status / Action**  
Included on the formulary  
Numbers likely to treat:  
CWH: 3-5 patients per year  
WMUH: 3-5 patients per year

**TA816 Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (10/08/2022)**

**Formulary status / Action**  
Fulvestrant is included on the formulary  
Alpelisib is not included on the formulary  
Add Alpelisib to the formulary following receipt of an application form from the Oncology Team  
Update: Application form included under Section 4.1

**TA817 Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (10/08/2022)**

**Formulary status / Action**  
Included on the formulary  
Numbers likely to treat:  
CWH: 2 patients per year  
WMUH: N/A

**TA818 Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (17/08/2022)**

**Formulary status / Action**  
Both included on the formulary  
Numbers likely to treat:  
CWH: 2-3 patients per year  
WMUH: N/A



**TA819 Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (17/08/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Add to the formulary following receipt of an application form from the Oncology Team**

**Update: Application form included under Section 4.1**

**TA820 Brolucizumab for treating diabetic macular oedema (31/08/2022)**

**Formulary status / Action**

**Included on the formulary**

**Numbers likely to treat:**

**CWH: <5 per year**

**WMUH: 0 per year**

**TA821 Avalglucosidase alfa for treating Pompe disease (24/08/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Not commissioned site as not a Specialist Metabolic Centre**

**TA822 Melphalan for haematological disease before allogeneic haematopoietic stem cell transplant (14/09/2022)**

**Nil - Terminated Appraisal**

**TA823 Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (28/09/2022)**

**Formulary status / Action**

**Included on the formulary**

**Numbers likely to treat:**

**CWH: 2-3 patients per year**

**WMUH: N/A**

**TA824 Dexamethasone intravitreal implant for treating diabetic macular oedema (14/09/2022)**

**Formulary status / Action**

**Included on the formulary**

**Numbers likely to treat:**

**CWH: 5-20 per year**

**WMUH: 0 per year**

**TA825 Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (21/09/2022)**

**Formulary status/Action**

**Nil - Not a commissioned site as not a Specialist Rheumatology Centre**

**TA826 Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (21/09/2022)**

**Nil - Terminated appraisal**

**TA827 Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (05/10/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Action: Add to the formulary following receipt of an application form from the Oncology Team**

**Update: Application form included in Section 4.1**

**TA828 Ozanimod for treating moderately to severely active Ulcerative Colitis (05/10/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Action: Add to the formulary following receipt of an application form from the Gastroenterology Team**

**TA829 Upadacitinib for treating active ankylosing spondylitis (30/09/2022)**



**Formulary status / Action**

**Included on the formulary**

**Numbers likely to treat:**

**CWH: 5-10 patients per year**

**WMUH: 15-20 patients per year**

**TA830 Pembrolizumab for adjuvant treatment of renal cell carcinoma (19/10/2022)**

**Formulary status / Action**

**Included on the formulary**

**Numbers likely to treat:**

**CWH: To be confirmed - To confirm commissioning status**

**WMUH: N/A**

**TA831 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (05/10/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Action: Add to the formulary following receipt of an application form from the Oncology Team**

**TA832 Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (19/10/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Action: Add to the formulary following receipt of an application form from the Gynaecology Team**

**Update: Application form included in Section 4.1**

**TA833 Zanubrutinib for treating Waldenstrom's macroglobulinaemia (19/10/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Action: Add to the formulary following receipt of an application form from the Haematology Team**

**TA834 SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (12/10/2022)**

**Nil - Terminated appraisal**

**TA835 Fostamatinib for treating refractory chronic immune thrombocytopenia (19/10/2022)**

**Formulary status / Action**

**Not included on the formulary**

**Action: Add to the formulary following receipt of an application form from the Haematology Team**

**b) NICE Highly Specialised Technology Appraisals published since last meeting**

**1 HST appraisal published in May 2022**

**HST20 - Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (05/05/2022)**

**Formulary status / Action**

**Action: Nil - CWFT is not a commissioned site for treating under this NICE HST**

**1 HST appraisal published in July 2022**

**HST21 - Setmelanotide for treating obesity caused by LEPR or POMC deficiency (06/07/2022)**

**Formulary status / Action**

**Action: Nil - CWFT is not a commissioned site for treating under this NICE HST**

**c) NICE TA adherence table 2021/22**

**Outcome: Approved for uploading to Trust Intranet**



d) **NICE HST Adherence Table 2021/22 )**  
**Outcome: Approved for uploading to Trust Intranet**

#### **4.5 IVIG requests**

- **IVIG Issues for June 2022 - CWH Site**

There were 5 IVIG issues in June 2022, with 3 new requests

**Outcome: Noted**

- **IVIG Issues for June 2022 - WMUH Site**

There were 7 IVIG issues in June 2022, with 3 new requests

**Outcome: Noted**

- **IVIG issues for July 2022- CWH Site**

There were 11 IVIG issues in July 2022, with 5 new requests

**Outcome: Noted**

- **IVIG issues for July 2022 - WMUH Site**

There were 11 IVIG issues in July 2022, with 6 new requests:

**Outcome: Noted**

- **IVIG Issues for August 2022 - CWH Site**

There were 10 IVIG issues in July 2022, with 8 new requests

**Outcome: Noted**

- **IVIG issues for August 2022- WMUH Site**

There were 12 IVIG issues in August 2022, with 6 new requests:

**Outcome: Noted**

- **IVIG Issues for September 2022 - CW Site**

There were 10 IVIG issues in September 2022, with 7 new requests:

**Outcome: Noted**

- **IVIG issues for September 2022- WMUH Site**

There were 10 IVIG issues in September 2022, with 4 new requests:

**Outcome: Noted**

**Outcome: Noted**

#### **4.6 Items for noting**

- **Quarterly Controlled Drug Summary Report - Q1 2022/23**

Quarterly Controlled Drug Summary Report for Q1 2022/23

**Outcome: Noted**

- **Quarterly Controlled Drugs Accountable Officer Report - Q1 2022/23**

Quarterly CD Accountable Officer Report for Q1 2022/23

**Outcome: Noted**

- **Medication Safety Bulletin - Medication Interactions**

Medication Safety Bulletin relating to Medication Interactions

**Outcome: Noted**

- **Medication Safety Bulletin - Monkeypox**

Medication Safety Bulletin relating to Monkeypox

**Outcome: Noted**

- **Medication Safety Bulletin - World Patient Safety Day**





Medication Safety Bulletin relating to World Patient Safety Day

**Outcome: Noted**

- **Medication Safety Bulletin - VTE**

Medication Safety Bulletin relating to VTE

**Outcome: Noted**

- **MHRA Drug Safety Update - July 2022**

MHRA update for July 2022

**Outcome: Noted**

- **MHRA Drug Safety Update - August 2022**

MHRA update for August 2022

**Outcome: Noted**

- **MHRA Drug Safety Update - September 2022**

MHRA update for September 2022

**Outcome: Noted**

- **MHRA Drug Safety Update - October 2022**

MHRA update for October 2022

**Outcome: Noted**

#### **4.7 Meeting minutes for noting**

- **Antimicrobial Stewardship Group meeting minutes - October 2022**

Minutes from Antimicrobial Stewardship Group meeting held October 2022

**Outcome: Noted**

- **Medication Safety Group meeting minutes - September 2022**

Minutes from Medical Safety Group meeting held September 2022

**Outcome: Noted**

- **Medication Safety Group meeting minutes - November 2022**

Minutes from Medical Safety Group meeting held November 2022

**Outcome: Noted**

#### **5. Any other business**

Nil

#### **6. Date of next meeting**

Next meeting

Date

- **30<sup>th</sup> January 2023**

**Time: 8am-9am**

**Location: via Teams**